Wedbush Reiterates Outperform on Nuvation Bio, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has reiterated an Outperform rating on Nuvation Bio (NYSE:NUVB) and maintained a $5 price target.

May 15, 2024 | 1:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst David Nierengarten has reiterated an Outperform rating on Nuvation Bio and maintained a $5 price target, indicating confidence in the company's future performance.
The reiteration of an Outperform rating and the maintenance of a $5 price target by a reputable analyst suggests positive sentiment and confidence in Nuvation Bio's future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100